Sakar Healthcare Ltd (SAKAR) AI Stock Analysis

• Market Cap: ₹7.83B
• Dividend Yield: N/A
• Average Volume (3M): 14.71K
• Price to Earnings (P/E): 39.6
• Beta (1Y): 0.54
• Revenue Growth: 21.65%
• EPS Growth: 73.16%
• Country: IN
• Employees: 325
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.11
• Shares Outstanding: 21,949,910
• 10 Day Avg. Volume: 21,659
• 30 Day Avg. Volume: 14,715
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹365.00
• Price Target Upside: 2.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 64 Neutral
• Price Target: ₹365.00 ▲(2.38% Upside)

Sakar Healthcare Ltd's overall score is driven by strong financial performance, particularly in revenue growth and operational efficiency. Technical indicators suggest a neutral market position, while valuation metrics indicate the stock is fairly priced. The absence of earnings call and corporate events data limits additional insights.

Sakar Healthcare Ltd Business Overview & Revenue Model

Company Description

Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.

How the Company Makes Money

Sakar Healthcare Ltd makes money through the sale of its pharmaceutical products, which include a variety of formulations such as injectables, tablets, capsules, and liquid orals. The company generates revenue by supplying these products to hospitals, clinics, pharmacies, and other healthcare facilities in domestic and international markets. Additionally, Sakar Healthcare engages in contract manufacturing, producing pharmaceutical products for other companies, which serves as an additional revenue stream. The company may also have strategic partnerships or collaborations with other pharmaceutical companies, which can enhance its market reach and contribute to its overall earnings.

Sakar Healthcare Ltd Financial Statement Overview

Summary

Sakar Healthcare Ltd shows strong revenue growth and improving operational efficiency, with increasing EBIT margins and a stable equity position. However, challenges in maintaining consistent profitability and managing cash flow effectively persist.

Income Statement

Sakar Healthcare Ltd has demonstrated a consistent increase in revenue over the years, with a notable revenue growth rate of 15.2% in 2025 compared to 2024, and 15.6% from 2024 to 2023. The Gross Profit Margin has been fluctuating but remained strong, standing at 24.1% for 2025. However, the Net Profit Margin has been lower at 9.9% for 2025, indicating higher operating costs or expenses. The EBIT margin improved to 16.2% in 2025 from 12.9% in 2024, showing operational efficiency. Nonetheless, the drop in Gross Profit Margin from 45.3% in 2024 to 24.1% in 2025 is a concern.

Balance Sheet

The company's Debt-to-Equity ratio has improved, decreasing from 0.30 in 2024 to 0.26 in 2025, indicating a reduction in leverage. The Return on Equity (ROE) has been stable, with 6.1% in 2025, showcasing moderate profitability relative to equity. The Equity Ratio stood at 68.8% in 2025, reflecting a strong equity position. Despite the positive trends, the ratio of Total Debt to Stockholders' Equity remains notable, requiring careful monitoring.

Cash Flow

The Free Cash Flow has been negative but shows signs of improvement, with a 61.4% increase in 2025 compared to 2024. The Operating Cash Flow to Net Income ratio was strong at 1.07 in 2025, indicating that the company is efficiently converting its net income into cash. However, the Free Cash Flow to Net Income ratio remains negative, suggesting challenges in covering capital expenditures solely through operational earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2021	Dec 2021
Income Statement
Total Revenue	1.70B	1.78B	1.54B	1.33B	947.39M	1.28B
Gross Profit	468.15M	427.91M	699.59M	598.12M	432.46M	534.12M
EBITDA	463.14M	509.44M	393.27M	341.03M	237.73M	315.72M
Net Income	148.62M	175.02M	116.71M	127.59M	106.83M	152.43M
Balance Sheet
Total Assets	0.00	4.15B	3.95B	3.36B	1.78B	2.68B
Cash, Cash Equivalents and Short-Term Investments	5.27M	3.09M	4.66M	35.23M	824.65K	71.36M
Total Debt	0.00	749.55M	793.52M	1.11B	425.97M	928.62M
Total Liabilities	-2.69B	1.30B	1.33B	1.63B	793.40M	1.40B
Stockholders Equity	2.69B	2.85B	2.62B	1.73B	984.52M	1.27B
Cash Flow
Free Cash Flow	0.00	-135.52M	-350.93M	-468.81M	-209.69M	-618.33M
Operating Cash Flow	0.00	187.31M	244.67M	353.14M	145.77M	356.99M
Investing Cash Flow	0.00	-307.09M	-515.39M	-743.77M	-468.33M	-903.72M
Financing Cash Flow	0.00	118.22M	274.45M	410.96M	320.33M	546.21M

Sakar Healthcare Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 356.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SAKAR, the sentiment is Positive. The current price of 356.5 is above the 20-day moving average (MA) of 344.25, above the 50-day MA of 341.23, and above the 200-day MA of 304.29, indicating a bullish trend. The MACD of 6.16 indicates Negative momentum. The RSI at 55.86 is Neutral, neither overbought nor oversold. The STOCH value of 58.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SAKAR.

Sakar Healthcare Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	67 Neutral	₹5.86B	10.92	8.08%	―	9.15%	88.32%
SAKAR	64 Neutral	₹7.83B	39.59	―	―	21.65%	73.16%
INDSWFTLAB	58 Neutral	₹6.02B	2.90	21.35%	―	-68.96%	-30.30%
KILITCH	57 Neutral	₹5.92B	19.89	13.20%	―	37.51%	122.52%
MEDICAMEQ	54 Neutral	₹4.13B	41.20	3.34%	0.33%	-9.90%	33.18%
NECLIFE	43 Neutral	₹3.26B	-1.81	-11.89%	―	-3.41%	-3028.44%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sakar Healthcare Ltd Corporate Events

Sakar Healthcare Ltd Confirms Compliance with SEBI Regulations for Q2 2025

Sakar Healthcare Ltd has submitted a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending June 30, 2025. This announcement confirms the dematerialization of securities and their listing on stock exchanges, ensuring compliance with regulatory requirements and maintaining transparency for stakeholders.